Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-7.21%
-7.80%
+0.43%
-0.38%
+7.44%
PFE
Pfizer
$24.65
Chart
$24.58 (+0.28%)
$23 (+7.17%)
$26.28 (-6.20%)
$28.82 (-14.47%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-7.21%
-7.80%
+0.43%
-0.38%
+7.44%
PFE
Pfizer
Current Price
$24.65
Login to view Pfizer (PFE) recommendation from the last 90 days from financial news and social media.
Chart
$24.58 (+0.28%)
$23 (+7.17%)
$26.28 (-6.20%)
$28.82 (-14.47%)
PFE Latest Analysis
The Zacks Analyst Blog Highlights Pfizer Novo Nordisk and Eli Lilly. Pfizer beats Q2 estimates with rising oncology sales new drug launches and strong Seagen-driven portfolio growth.
Today
Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight. Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 |. DelveInsight The outlook for the gastric cancer treatment market appears favorable fueled by progress in targeted therapies and immunotherapies. Traditionally platinum-based chemotherapy has served as the primary treatment for early-stage gastric cancer underscoring the demand for more effective alte
Mon Aug 11, 2025
Pfizers Options Frenzy: What You Need to Know. Whales with a lot of money to spend have taken a noticeably ish stance on Looking at options history for Pfizer (NYSE:) we detected 13 trades.If we consider the specifics of each trade it is accurate to state that 53% of the investors opened trades with ish expectations and 38% with bearish.From the overall spotted trades 6 are puts for a total amount of $378835 and 7 calls for a total amount of $258682.After evaluating the trading volumes and Open
Mon Aug 11, 2025
Cancer Cachexia Clinical Trial Pipeline Shows Potential with Active Contributions from 18 Key Companies | DelveInsight. Cancer Cachexia Clinical Trial Pipeline Shows Potential with Active Contributions from 18 Key Companies |. DelveInsightThe cancer cachexia therapeutics market is gaining traction due to the rising global cancer burden and high prevalence of cachexia in advanced-stage patients. With limited approved treatments there'.s growing demand for therapies that address weight los
Thu Aug 7, 2025
Global Renal Transplant Therapeutics Market is Expected to Cross ~USD 18 Billion by 2032 | DelveInsight. Global Renal Transplant Therapeutics Market is Expected to Cross ~USD 18 Billion by 2032 |. DelveInsightThe demand for renal transplant therapeutics is increasing due to several important factors. Chief among these is the global rise in kidney transplant procedures driven by the growing incidence of chronic kidney disease renal failure and end-stage renal disease (ESRD) all of which can c
Wed Aug 6, 2025
Pfizer raises 2025 EPS guidance to $2.90–$3.10 while targeting margin expansion through $7.7B cost savings by 2027.
Tue Aug 5, 2025
Pfizer Q2 Earnings Beat Estimates Oncology Drives Top-Line Growth. PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year fueled by rising oncology sales and cost cuts.
Tue Aug 5, 2025
Pfizer Cost-Cut Initiatives More Than Offset Tariffs Impact Raises Outlook. On Tuesday) reported second-quarter 2025 adjusted earnings of 78 cents compared to 60 cents a year ago beating the.Pfizer'.s sales jumped 10% year over year to $14.70 billion above the consensus of $13.41 billion reflecting an .The operational increase was primarily driven by an increase in revenues for the Vyndaqel family Comirnaty Paxlovid Padcev Eliquis and several other products across categories despite the unfa
Tue Aug 5, 2025
Dow Surges Over 100 Points. Pfizer Earnings Top Views. United States stocks traded higher this morning with the Dow Jones index gaining more than 100 points on Tuesday.Following the market opening Tuesday the Dow traded up 0.25% to 44285.50 while the NASDAQ climbed 0.25% to 21106.41. The S&.P 500 also rose gaining 0.19% to 6341.77.Check This Out: Consumer discretionary shares jumped by 0.7% on Tuesday.In trading on Tuesday energy stocks fell by 0.4%.) reported better-than-expected second-quar
Tue Aug 5, 2025
Pfizer Smashes Earnings Forecasts And Raises Outlook. Shares Jump. Pfizer stock jumped early Tuesday after the drugmaker raised its earnings outlook on the back of a strong second-quarter report.The post Pfizer Smashes Earnings Forecasts And Raises Outlook. Shares Jump appeared first on Investor'.s Business Daily.
Tue Aug 5, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings